Key Points Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD). Auvelity sales soared 69% in Q3. 10 stocks we like better than Axsome Therapeutics › Axsome Therapeutics (NASDAQ: AXSM) shares soared to close out the year. The company released two items of news today. Investors see one in particular as a meaningful catalyst for the biopharmaceutical company that specializes in de ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on December 18 that Johnson & Johnson received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO, co-formulated with ENHANZE® for people with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer. RYBREVANT FASPRO holds approval across all indications of RYBREVAN ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. As these policy overhangs fade, Morgan Stanley anticipates a shift in market attention back to the industry’s core financial and operational performance. Later, on ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the low priced stocks to buy with high upside potential. On December 12, Bank of America raised the firm’s price target on Ocular Therapeutix to $21 from $18 and maintained a Buy rating on the shares. After hosting CEO Pravin Dugel to review upcoming corporate milestones, the firm highlighted the development strategy for AXPAXLI, supported by pivotal trials in both wet AMD and diabetic retinopathy. BofA remains optimistic about the drug’s unique competitive a ...

We drive into the future using only our rearview mirror, as famously said by Canadian scholar Marshall McLuhan. With 2025 drawing to a close, it's the perfect time to reflect on how some of the stocks we profiled performed over the year and to look ahead for potential hidden gems in the New Year. Below is a list of lesser-known stocks that went on to deliver significant returns, which we identified early.Palvella Therapeutics Inc. (PVLA)Palvella is a clinical-stage biopharmaceutical company, exclusively fo ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays analyst Etzer Darout raised the firm’s price target on Iovance Biotherapeutics to $10 from $9, while keeping an Overweight rating on the shares. This announcement was made as part of the firm’s 2026 projections, where it revised its valuation targets for the biotech industry. Earlier in Q3 2025, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) highlighted a total product rev ...

Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which change ...

专注于开发和商业化中枢神经系统(CNS)疾病新型疗法的生物制药公司Axsome Therapeutics(AXSM.US) 周三宣布，美国食品药品监督管理局(FDA)已对其提交的、旨在扩大其抑郁症疗法AXS-05(商品名： Auvelity)适应症至阿尔茨海默病激越症状的上市申请授予优先审评资格。该公司在一份声明中表示，针 对AXS-05的补充新药申请，FDA已将2026年4月30日设定为目标审评完成日期。受此消息提振，截至发 稿，Axsome周三美股盘前涨超7%。 AXS-05(右美沙芬-安非他酮)是一种口服N-甲基-D-天冬氨酸受体拮抗剂、sigma-1激动剂和氨基酮 CYP2D6抑制剂。AXS-05利用右美沙芬和安非他酮的专利配方和剂量，以及Axsome的代谢抑制技术， 来调节成分的输送。AXS-05的右美沙芬成分是非竞争性NMDA受体拮抗剂，也称为谷氨酸受体调节剂 和σ-1受体激动剂。AXS-05的安非他酮成分用于增加右美沙芬的生物利用度，并且是去甲肾上腺素和多 巴胺再摄取抑制剂。这种新型疗法有望改善以情绪困扰、言语和身体攻击、破坏性易怒和脱抑制为特征 的AD激越。 Axsome首席执行官Herrio ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.Oz-V targets ROR2, an important receptor ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment of Alzheime ...